On Tuesday, Diplomat Pharmacy Inc (NYSE:DPLO)’s shares declined -9.06% to $35.14.
Diplomat Pharmacy, Inc. (DPLO) is aware of unusual market activity in its stock recently, potentially in respect to a deal in which Diplomat was incorrectly referenced. Diplomat is aware of a recent development regarding Depomed Inc., and Horizon Pharma PLC, in which it is not involved. Diplomat heard from an investor recently that the Diplomat name was incorrectly referenced instead of Depomed, in a discussion between that investor and a bank earlier recently. We reference such statement only to explain the potential market confusion and we are not commenting on the validity of the statement in any respect. Diplomat has noted that in terms of both shares traded (relative to usual trading volumes) and stock price decline thus far recently, its stock is unusually correlated to Depomed Inc. and Horizon Pharma PLC.
Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers.
Kite Pharma Inc (NASDAQ:KITE)’s shares gained 0.13% to $61.34.
Kite Pharma, Inc. (Kite) (KITE) declared that it has expanded its partnership with the Netherlands Cancer Institute (NKI). Kite and the NKI have reached a contract under which Kite will receive from the NKI the exclusive option to license multiple T cell receptor (TCR) gene sequences for the development and commercialization of cancer immunotherapy candidates targeting solid tumors. Kite has also expanded its access to additional resources and research facilities through a master services agreement with the NKI.
Kite Pharma EU, based in Amsterdam, will be conducting preclinical research related to candidates under the agreement with NKI. Kite Pharma EU is comprised of a leading team of immuno-oncology researchers and collaborators, counting Professor Dr. Ton N. M. Schumacher, who serves as Chief Scientific Officer of Kite Pharma EU. Professor Dr. Schumacher, a pioneer in T cell biology and gene therapy, is a developer of Kite’s proprietary TCR-GENErator(TM) discovery platform, an industry-leading R&D engine for rapid, high-throughput identification of TCR-based product candidates.
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies.
At the end of Tuesday’s trade, TerraForm Global Inc (NASDAQ:GLBL)‘s shares dipped -4.61% to $8.27.
TerraForm Global (GLBL), a globally diversified owner and operator of clean energy projects, declared that it closed on the acquisition from Renova Energia of two operating wind energy projects that are part of the original TerraForm Global IPO portfolio.
The Salvador and Bahia wind energy projects are located in Brazil and generate 294 megawatts (MW) AC of capacity in aggregate. The projects were purchased with a combination of TerraForm Global Class A common stock and cash that was allocated from the TerraForm Global IPO proceeds.
TerraForm Global, Inc. owns and operates renewable energy generation assets worldwide. It generates electricity through solar, wind, and hydro-electric projects with a total combined capacity of 987.8 megawatts.
TG Therapeutics Inc (NASDAQ:TGTX), ended its Tuesday’s trading session with -3.13% loss, and closed at $12.07.
TG Therapeutics, Inc. (TGTX) declared the initiation of a Phase 1/2 clinical study that will investigate the use of TGR-1202, the Company’s oral PI3K delta inhibitor and TG-1101 (ublituximab), the Company’s glycoengineered anti-CD20 monoclonal antibody in combination with pembrolizumab the anti-PD-1 immune checkpoint inhibitor, in patients with relapsed or refractory CLL. This will be the first clinical trial evaluating the safety, tolerability and effectiveness of the triple combination of a PI3K delta inhibitor with an anti-CD20 mAb and an anti-PD-1 checkpoint inhibitor.
Dr. Anthony Mato, an assistant professor in the Perelman School of Medicine at the University of Pennsylvania, Director of the Center for CLL at Penn’s Abramson Cancer Center and Study Chair of the Phase 1/2 study added, “We look forward to collaborating with TG Therapeutics on this novel combination clinical trial. Our center has been intimately involved with T-cell therapies for hematologic diseases and we are firm believers in the promise they hold broadly for cancer patients. The combination of TG-1101 and TGR-1202 has demonstrated unique tolerability and activity which we believe represents a strong backbone on which to add additional novel therapies. We believe the novel approach utilized in this study, where we will induce a response with TG-1101 and TGR-1202, followed by consolidation with anti-PD-1 therapy, could maximize the potential benefit of T-cell therapy in CLL. We are thrilled to have moved this study from concept to first patient enrolled in just a few months, and look forward to offering patients with advanced CLL new options with this novel triple combination.”
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for b-cell malignancies and autoimmune diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
